IRONWOOD PHARMACEUTICALS INC

Ironwood Pharmaceuticals is a biotechnology company focused on developing and commercializing therapies for gastrointestinal and rare diseases. The company's primary marketed product is linaclotide, a guanylate cyclase type-C (GC-C) agonist sold under the brand names LINZESS and CONSTELLA for treating irritable bowel syndrome with constipation, chronic idiopathic constipation, and pediatric functional constipation. Linaclotide generates revenue through commercialization agreements with larger pharmaceutical partners including AbbVie, AstraZeneca, and Astellas Pharma.

The company's pipeline includes IW-3300, a GC-C agonist in development for visceral pain conditions such as interstitial cystitis/bladder pain syndrome and endometriosis, and Apraglutide, a long-acting glucagon-like peptide-2 analog being evaluated for short bowel syndrome in patients dependent on parenteral support and for acute graft versus host disease. These programs represent the company's expansion beyond its core GI franchise into orphan and specialty indications.

Ironwood maintains headquarters in Boston, Massachusetts, and operates internationally. The company was incorporated in Delaware in 1998, originally under the name Microbia before rebranding to Ironwood Pharmaceuticals in 2008. The organization operates at a modest scale relative to large-cap pharmaceutical manufacturers, with a market capitalization of approximately $0.5 billion.